论文部分内容阅读
目的探讨严重烧伤患者采用不同重组人生长激素治疗的临床效果及安全性比较。方法对我院接收治疗的80例严重烧伤患者入院资料进行分析,将患者根据其入院时间顺序分为两组。对照组采用中山海济药业生产的海之元rhGH治疗,实验组采用北京双鹭药业生产的rhGH治疗,比较两组患者临床治疗效果等指标。结果两组患者采用不同重组人生长激素治疗后,实验组患者IGF-I指标为(126.23±42.99g/L)、白蛋白为(33.29±6.72g/L)、前白蛋白指标为(0.15±0.07g/L)、转铁蛋白指标为(2.40±0.45g/L)和对照组患者相比差异没有显著性(P>0.05)。结论重组人生长激素临床效果与同类产品相似,治疗后对肝肾功能、血常规、空腹血糖等指标影响较小,不良反应少,值得推广使用。
Objective To investigate the clinical effects and safety of patients with severe burns treated with different recombinant human growth hormone. Methods 80 patients admitted to our hospital admitted to hospital for treatment of severe burns were analyzed, the patients were divided into two groups according to their admission time sequence. The control group was treated with sea yuan rhGH produced by Zhongshan Haizhu Pharmaceutical Co., Ltd. The experimental group was treated with rhGH produced by Beijing Shuanglu Pharmaceutical Co., Ltd. The clinical effects of the two groups were compared. Results After treatment with different recombinant human growth hormone, the IGF-I index of the experimental group was (126.23 ± 42.99g / L), the albumin was (33.29 ± 6.72g / L) and the prealbumin index was (0.15 ± 0.07g / L). There was no significant difference in transferrin (2.40 ± 0.45g / L) and control group (P> 0.05). Conclusion The clinical effect of recombinant human growth hormone is similar to that of similar products. After treatment, it has little effect on liver and kidney function, blood routine, fasting blood glucose and other indicators, and has few adverse reactions. It is worth promoting.